Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a ...

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes ...

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped ...

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...

The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S.

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...